Berdeja JG et al. Panobinostat from bench to bedside: Rethinking the treatment paradigm for multiple myeloma. Clin Lymphoma Myeloma Leuk 2021;21(11):752-65. Abstract
Berdeja JG et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). ASCO 2021;Abstract 8008.
Bladé J et al. Extramedullary disease in multiple myeloma: A systemic literature review. Blood Cancer J 2022;12(3):45. Abstract
Branagan AR et al. Clinical effectiveness and long-term serologic responses of COVID-19 vaccination in patients with multiple myeloma and Waldenström macroglobulinemia. ASH 2022;Abstract 4535.
Callander N et al. Analysis of transplant-eligible patients (pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the Griffin and Master studies. ASH 2022;Abstract 4557.
Chari A et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (pts): Final analysis of Griffin among clinically relevant subgroups. ASH 2022;Abstract 3238.
Delimpasi S et al. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Am J Hematol 2022;97(3):E83-6. Abstract
DeStefano CB et al. The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Semin Oncol 2022;49:19-26. Abstract
Dimopoulos MA et al. An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Ther Adv Hematol 2022;13:20406207221088458. Abstract
Dimopoulos MA et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: Final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 2022;[Online ahead of print]. Abstract
Dimopoulos MA et al. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphonma Myeloma Leuk 2022;22(7):460-73. Abstract
Einsele H et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma after 1-3 prior lines of therapy (LOT): CARTITUDE-2, cohort A. ASCO 2022;Abstract 8020.
Frede J et al. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol 2021;23(11):1199-211. Abstract
Grosicki S et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 2020;396(10262):1563-73. Abstract
Gulla A et al. Targeting autophagy to overcome resistance to immunogenic chemotherapy in high-risk multiple myeloma. ASH 2022;Abstract 3165.
Hartley-Brown M et al. Antibody-drug conjugate therapies in multiple myeloma—What’s next on the horizon? Explor Target Antitumor Ther 2022;3(1):1-10. Abstract
Hassoun H et al. Multivariable analyses of prognostic factors for progression-free survival (PFS) and complete response (CR) with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus rvd plus autologous stem cell transplantation (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM) in the Determinatino phase 3 trial. ASH 2022;Abstract 2110.
Ho M et al. Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. Leuk Lymphoma 2022;63(10):2403-12. Abstract
Kumar SK et al. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. ASH 2021;Abstract 84.
Leleu X et al. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: Differential mechanisms of action and recent clinical trial outcomes. Ann Hematol 2022;101(10):2123-37. Abstract
Lesokhin AM et al. Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). ASCO 2022;Abstract 8006.
Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 2021;127(22):4198-212. Abstract
Lonial S et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 2021;11(5):103. Abstract
Lonial S et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study. ASCO 2022;Abstract 8019.
Mateos M-V et al. MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. ASCO 2022;Abstract TPS8072.
McCaughan GJ et al. Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: A practical review. Br J Haematol 2022;199(2):190-204. Abstract
Minnema MC et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Updated results from MonumenTAL-1. ASCO 2022;Abstract 8015.
Mo CC et al. Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Rev Hematol 2021;14(8):697-706. Abstract
Moreau P et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387(6):495-505. Abstract
Nadeem O et al. A phase I/II study of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. ASH 2022;Abstract 4570.
Nadeem O et al. Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc) 2022;58(8):407-23. Abstract
Nooka AK et al. An end-of-study subgroup analysis of black patients from the phase 2 Griffin study of daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). ASH 2022;Abstract 4560.
Nooka AK et al. Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 trial. ASH 2022;Abstract 3246.
Nooka AK et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. ASCO 2022;Abstract 8007.
Ocio EM et al. Melflufen for the treatment of multiple myeloma. Expert Rev Clin Pharmacol 2022;15(4):371-82. Abstract
O’Donnell EK et al. A phase II study of once weekly carfilzomib, lenalidomide, dexamethasone, and isatuximab in newly diagnosed, transplant-eligible multiple myeloma (the SKylaRk Trial). ASH 2022;Abstract 3239.
O’Donnell EK et al. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv 2022;6(17):4967-74. Abstract
O’Donnell EK et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer 2022;128(10):1996-2004. Abstract
Richardson PG et al. Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): Characterization of subsequent antimyeloma therapies. ASH 2022;Abstract 247.
Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. ASCO 2022;Abstract LBA4.
Richardson PG et al. Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. ASH 2022;Abstract 568.
Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract
Rodriguez C et al. Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN. ASCO 2022;Abstract 8011.
Sborov DW et al. Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Final analysis of GRIFFIN. IMS 2022;Abstract OAB-057.
Sborov DW et al. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol 2022;199(3):355-65. Abstract
Silbermann R et al. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: patient reported outcomes from GRIFFIN. ASH 2022;Abstract 473.
Terpos E et al. Safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: A phase 1/2 study by the Hellenic Society of Hematology. EHA 2022;Abstract S178.
Touzeau C et al. Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: Results of the phase 2 study IFM 2018-04. ASCO 2022;Abstract 8002.
Tremblay G et al. Quality of life analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase 2b study. BMC Cancer 2021;21(1):993. Abstract
Tuazon SA et al. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J 2021;11(2):23. Abstract
Usmani SZ et al. DREAMM-9: Phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. EHA 2022;Abstract P942.
van de Donk NWCJ et al. Biological correlative analyses an updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B. ASCO 2022;Abstract 8029.
van de Donk NWCJ et al. Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: Updated phase 1b results for talquetamab (a GPRC5D x CD3 bispecific antibody) in combination with daratumumab. EHA 2022;Abstract S183.